Big deals understandably make investors nervous, but when the buyer in
question already has a record and reputation for overpaying in deals and
failing to reap all of the promised benefits, it's so much the worse.
That's the burden on Hologic (HOLX) now that it has announced a very large, and almost certainly transformative, acquisition of diagnostics company Gen-Probe (GPRO).
But as Hologic's own second quarter earnings suggest, the company
needed another avenue of growth and Gen-Probe just may fit the bill.
Please click here for more:
Hologic Must Make The Third Time A Charm
No comments:
Post a Comment